TABLE 3.
Neuropathologic diagnoses by contributing institution.
| Columbia | Emory | Mayo | MSSM | Rush | |
|---|---|---|---|---|---|
| Outcome | N = 105 | N = 156 | N = 331 | N = 88 | N = 228 |
| NIA Reagan a | |||||
| No AD | 2 (2%) | 21 (13%) | NA | 4 (5%) | 4 (2%) |
| Low likelihood | 30 (29%) | 45 (29%) | NA | 24 (27%) | 78 (34%) |
| Intermediate likelihood | 20 (19%) | 20 (13%) | NA | 16 (18%) | 82 (36%) |
| High likelihood | 48 (46%) | 68 (44%) | NA | 39 (44%) | 64 (28%) |
| Missing or unknown | 5 (5%) | 2 (1%) | NA | 5 (6%) | 0 |
| Derived AD outcome b | |||||
| Control | 16 (15%) | 64 (41%) | 58 (18%) | 22 (25%) | 51 (22%) |
| AD | 66 (63%) | 77 (49%) | 180 (54%) | 52 (59%) | 125 (55%) |
| Other | 18 (17%) | 13 (8%) | 93 (28%) | 9 (10%) | 52 (23%) |
| Missing or unknown | 5 (5%) | 2 (1%) | 0 | 5 (6%) | 0 |
Abbreviations: AD, Alzheimer's disease; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; MSSM, Mount Sinai School of Medicine; NIA, National Institute on Aging.
NIA Reagan score modified in accordance with Bennett et al. 63 : No AD: CERAD = No AD/None and Braak = Stage 0; Low Likelihood: CERAD = No AD/None and Braak ≥ Stage I OR CERAD = Possible/sparse and Braak = any stage OR CERAD = Probable AD/moderate and Braak ≤ Stage II; Intermediate Likelihood: CERAD = Probable/moderate and Braak ≥ Stage III OR CERAD = Definite/frequent and Braak ≥ Stage I and ≤ Stage IV; High Likelihood: CERAD = Definite AD/frequent and Braak ≥ Stage V.
For Mayo patients, this outcome is the reported diagnosis according to Mayo neurologist guidelines, as reported. 57 For all other patients: Control: CERAD = No AD/None or Possible/sparse and Braak ≤ Stage III; AD case: CERAD = Probable/moderate or Definite/frequent and Braak ≥ Stage IV; Other = all other combinations of CERAD and Braak.
NA = not applicable for Mayo patients because Mayo did not report CERAD measures.